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Abstract 
Doxorubicin (DOX)-induced cardiotoxicity is thought o be caused by free radical-mediated mechanisms. An in vivo rat 
model was developed to investigate the DOX-induced cascade of early biochemical changes focusing on the central role of 
the aldehydic lipid peroxidation products. Antioxidant status was evaluated by glutathione measurements. Creatine Kinase 
(CK) activity was measured as an index of cardiac injury. Development of functional abnormalities were documented by 
echocardiography. The results showed that aldehydes in rat plasma and heart issues increased significantly following DOX 
treatment. The changes occurred early, peaked around 2 h after DOX administration, and the levels declined or returned to 
baseline value within 8-24 h. Toxic aldehyde levels including malondialdehyde, hexanal and 4-hydroxy-non-2-enal also 
increased. Acyloin levels, metabolic products of aldehydes, increased early and then decreased in plasma, and there was a 
significant decrease in heart issues after DOX treatment. GSH levels decreased early, then increased by 24 h, while GSSG 
levels decreased initially, then increased after DOX treatment, suggesting early depletion of GSH and a later rebound 
phenomenon. CK levels were elevated after treatment. The functional abnormalities were documented by stress echocardio- 
graphy in some rats although the changes were not consistent at such an early stage following treatment. Our data confirmed 
the involvement of free radicals, and suggested that the cytotoxic aldehydes play a central role in initiating the steps that 
lead to functional impairment of the myocardium following DOX administration. Scavengers and the metabolic removal of 
some of the aldehydes also play a role in protecting the myocardium against injury. 
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1. Introduction 
The anthracycline antibiotic, doxorubicin (DOX, 
also known as adriamycin) is a potent broad spectrum 
chemotherapeutic agent that is effective against hu- 
man malignancies such as leukemias, lymphomas and 
many solid tumors, and is widely used in both pedi- 
atric and adult patients [1-4]. However, the clinical 
use of doxorubicin is limited by its severe, cumula- 
tive, dose-dependent cardiotoxicity [4,5]. DOX has 
both acute and chronic, long-term toxic effects on the 
heart. The acute effects are characterized by a variety 
of acute atrial and ventricular dysrhythmias, a peri- 
carditis-myocarditis syndrome, and acute hyperten- 
sive reactions occurring shortly after the administra- 
tion of the drug, which are usually transient and 
clinically manageable [6]. The long-term effects in- 
clude the insidious onset of cardiomyopathy that 
often leads to congestive heart failure. These life 
threatening effects often develop only after several 
weeks or months of treatment, and sometimes even 
years after therapy has been completed. The inci- 
dence of cardiotoxicity increases at cumulative doses 
in excess of 500 mg/m 2 and is age related. Younger 
children are at higher risk and DOX treatment in 
children may lead to a lifelong reduction in myocar- 
dial mass that, with further growth may result in 
decreased cardiac reserve [7,8]. 
The precise mechanism of DOX-induced cardio- 
toxicity is not entirely clear [9,10]. Although acute 
alterations in platelet-activating factor, prosta- 
glandins, histamine, and intracellular calcium have 
been implicated, drug-stimulated reactive oxygen 
metabolism that causes peroxidation of membrane 
lipids is thought o be most likely factor responsible 
for the development of cardiotoxicity [ 11-13]. 
The quinone structure of the anthracycline C ring 
has a highly reactive potential, and a 1-electron re- 
duction results in the formation of a semiquinone free 
radical in the presence of certain ravin enzymes and 
mitochondrial complex I- I I I  [14,15]. Under the aero- 
bic conditions existing in the myocardial cell, this 
semiquinone free radical intermediate can readily 
donate its unpaired electron to molecular oxygen to 
produce superoxide radical, which is a potent initiator 
of other oxygen radicals as well as activated oxygen 
species. The repetitive reduction and oxidation 
(known as redox cycling) of DOX generates 
semiquinone radicals, singlet oxygen, superoxide, and 
hydrogen peroxide. In the presence of a suitable 
transition metal catalyst (DOX-iron complex), hy- 
droxyl radicals form through a Fenton-type reaction 
[16]. Free radicals, especially the highly reactive 
hydroxyl radical, readily react with a variety of 
molecules and cause peroxidation of membrane lipids, 
resulting in membrane degradation, protein aggrega- 
tion and, ultimately, cell death [17,18]. 
Free radicals have very short half lives and are 
very difficult to measure. The major stable products 
of lipid peroxidation, saturated and unsaturated alde- 
hydes, are considered to be some of the few measur- 
able parameters indicative of lipid peroxidation in 
vivo [19]. In the present study, we have developed a
short-term, in vivo rat model in which DOX was 
given by a bolus injection, to investigate the DOX-in- 
duced cascade of early biochemical changes focusing 
on the central role of toxic aldehydes that initiate the 
process leading ultimately to cardiomyopathy. Some 
of the acyloins (3-hydroxyalkan-2-ones), pyruvate de- 
hydrogenase (PDH) catalyzed condensation products 
between pyruvate and saturated aldehydes, were also 
determined at the same time. Antioxidant status was 
evaluated by measurement of blood glutathione lev- 
els. Creatine Kinase (CK) levels were measured as an 
index of early myocardial injury. The development of
functional abnormalities following DOX treatment 
were documented by echocardiography. 
2. Materials and methods 
2.1. Animals and drug treatment 
Male Wistar rats (Charles River, Montreal, Canada, 
350-400 g) were used. Animals were housed in 
stainless steel cages and maintained under a con- 
trolled environment ( emperature 24°C, relative hu- 
midity 50-55%, light cycle 06:00 h to 18:00 h), and 
were allowed free access to commercial rat chow 
(PROLAB R-M-H 1000, AGWAY, St. Mary's, OH) 
and tap water ad libitum. A total of 36 rats were 
randomly divided into six groups. Twelve rats served 
as control. To determine whether diurnal variation 
exists in the levels of any of the measured parame- 
ters, 4 rats were injected with 0.9% NaC1 vehicle 
solution intraperitoneally each time, at 9 a.m., 1 p.m. 
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and 5 p.m., respectively. The rats were sacrificed by 
exsanguination 1 h later under sodium pentobarbital 
(Somnotol, MTC Pharmaceuticals, Cambridge, On- 
tario, Canada) injection anesthesia. Blood samples 
were taken from femoral vein, and the heart was 
rapidly removed and frozen in liquid nitrogen for 
later analysis. For the five experimental nimal groups 
(4 rats in each group), rats were treated with a bolus 
injection of 10 mg/kg  of DOX (Adria Laboratories, 
Columbus, OH) in 0.9% NaC1 solution intraperi- 
toneally, and were sacrificed at 1 h, 2 h, 4 h, 8 h and 
24 h after DOX injection. The experimental protocol 
and all procedures were approved by the review 
board of the Animal Facility of the Hospital for Sick 
Children Research Institute. 
2.2. Measurement of aldehydes and acyloins 
Aldehydes and acyloins in plasma nd heart issues 
were measured by a newly developed method in our 
laboratory using capillary column gas chromatogra- 
phy negative-ion-chemical onization mass spectrom- 
etry (NICIGC-MS) [20]. Ethanal was excluded from 
this study because of possible contamination from 
solvents. The acyloins we have monitored included 
3-hydroxyheptan-2-one, 3-hydroxyoctan-2-one, 3-hy- 
droxynonan-2-one, 3-hydroxydecan-2-one and 3-hy- 
droxydodecan-2-one. The characteristic ons for se- 
lected ion recording (SIR) were 126, 140, 244, 258 
and 287, respectively. Since the standard acyloins 
were not commercially available, their concentrations 
were estimated according to their relevant aldehydes. 
The coefficient of variability (CV) for within-run and 
between-run assay precision for measuring aldehydes 
was assessed using 10 replicate samples of 5 separate 
experiments, and was found to be between 5-10%. 
2.3. Assay of glutathione 
Reduced and oxidized glutathione (GSH and 
GSSG) in whole blood were separated by HPLC and 
quantitated using an electrochemical detector [21]. 
0.2 ml of blood was added to 1.3 ml mobile phase for 
GSH, and 0.2 ml of blood was added to 1.0 ml 
mobile phase and 0.3 ml N-ethylmaleimide forGSSG, 
respectively. Samples were mixed well and cen- 
trifuged at 10000 rpm for 5 min. The supernatants 
were stored at -80°C, and were analyzed within 24 
h. 
2.4. Creatine kinase (CK) activity 
Plasma CK activity was measured by Kodak Ek- 
tachem 700 Analyzer (Kodak Canada, Toronto) within 
24 h. 
2.5. Echocardiography 
Systolic blood pressure, and 2-dimensional tar- 
geted m-mode chocardiography in all 12 control rats 
and 2 of each experimental group rats were measured 
using a Programmed Electro-Sphygmomanometer 
PE-300 (Narco Bio-Systems, Houston, TX), and an 
ATL Ultramark 9 HDI ultrasound system (Advanced 
Technology Laboratories, Bothel, WA) equipped with 
a 7 or 4 MHz broadband phased array transducer, 
respectively. The relationship between heart rate cor- 
rected velocity of circumferential fiber shortening 
(Vcf c) and meridional wall stress was used as a mea- 
sure of contractility [7]. 
2.6. Statistical analysis 
ANOVA (single-factor) and F-test of two-sample 
for variances was used to check the possible diurnal 
variation of aldehydes, acyloin and glutathione mea- 
surements within the control group. Since there was 
no significant diurnal variation during the experiment 
period observed, all control data were combined as 
one group. Student -test of unpaired two-sample for 
means were calculated for aldehyde and acyloin con- 
centrations, GSH and GSSG levels, and CK activities 
from control and experimental groups. P< 0.05 
(two-tail) was considered significant for all analyses. 
To assess contractility, Vcf c and meridional wall 
stress were analyzed by linear regression analysis, 
and a normal relationship defined from control ani- 
mals. Values significantly below the normal regres- 
sion line may indicate impaired contractility, points 
above suggest an enhancement. The change in the 
experimentally determined Vcf c following DOX was 
considered an indicator of the effect of treatment. 
3. Results 
Fig. 1 shows total aldehyde concentrations in rat 
plasma (A) and heart (B) at various times after 10 
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Fig. 1. Total aldehydes in rat plasma and heart. Total aldehyde 
concentrations in rat plasma and heart (A, plasma; B, heart). Data 
presented as mean± SD. * P < 0.01. 
Fig. 2. Total acyloins in rat plasma and heart. Total acyloin 
concentrations in rat plasma and heart (A, plasma; B, heart). Data 
presented as mean± SD. * P < 0.01, # P < 0.05. 
mg/kg of bolus injection of DOX intraperitoneally. 
Total aldehydes in rat plasma and heart tissue in- 
creased significantly, peaked at 2 hours following in 
vivo DOX treatment. The aldehyde levels declined or 
returned to control values 8-24 h after DOX adminis- 
tration. Fig. 2 shows the changes of acyloins in rat 
plasma (A) and heart (B) after DOX treatment. Total 
acyloin levels in rat plasma increased at 1 h after 
Table 1 
Aldehydes and acyloins concentration i rat plasma following doxorubicin treatment 
Aldehydes and Acyloins Rat-control Rat-1 h Rat-2 h Rat-4 h Rat-8 h Rat-24 h 
(n = 12) (n = 4) (n = 4) (n = 4) (n = 4) (n = 4) 
Propanal 117.0 ± 20.9 211.5 + 16.5 * 318.5 + 13.5 * 252.4 _+ 22.1 * 162.5 _ 21.4 * 139.8 _+ 11.7 
Butanal 160.4 ± 42.5 204.6 _+ 16.2 286.4 ± 68.8 * 217.4 ___ 37.5 * 164.5 ± 16.7 159.2 _+ 19.0 
Pentanal 85.3 ± 13.2 108.0 _+ 13.1 * 154.2 ± 48.7 * 129.6 _+ 42.0 * 77.2 _+ 13.5 82.3 ___ 18.2 
Furfural 23.2 _+ 4.6 20.1 ± 1.4 29.5 ± 9.8 39.5 _+ 12.9 * 34.4 ± 5.7 * 27.8 _+ 9.3 
Hexanal 287.5 ± 35.6 399.6 ± 66.4 * 505.3 _+ 41.2 * 346.7 _+ 59.5 * 320.4 ± 80.5 277.2 _+ 49.2 
trans-2-Hexenal 16.7 _+ 1.4 18.2 -+- 5.0 18.7 _+ 4.8 19.4 ± 4.6 16.2 _+ 4.1 17.5 ± 3.9 
Heptanal 182.7 _+ 35.6 184.3 + 18.9 228.4 ± 85.7 195.3 + 65.0 184.9 + 40.6 164.9 _+ 29.1 
trans-2-Heptenal 104.4 _+ 19.2 210.1 _+ 78.8 * 357.8 +_ 89.6 * 209.9 _+ 26.9 * 115.4 _+ 37.1 161.2 + 102.8 
trans,trans-2,4-Heptadienal 16.8 _+ 3.9 21.0 +_ 4.1 22.0 4- 9.0 17.3 _+ 5.1 17.1 +_ 6.8 15.7 ± 2.5 
Octanal 219.0 +_ 34.9 341.3 _+ 18.5 * 373.5 + 84.3 * 260.2 +_ 36.3 234.0 _+ 45.9 206.8 + 40.7 
trans-2-Octenal 23.0 _+ 5.7 28.5 _+ 6.4 35.2 +_ 8.3 * 25.3 _+ 7.0 21.0 ± 7.3 21.1 ± 7.4 
Nonanal 57.0 + 18.7 85.1 ± 5.9 * 133.2 ± 14.9 * 107.8 + 11.0 * 80.9 ± 17.8 * 69.9 _+ 19.1 
trans-2-Nonenal 123.3 _+ 16.2 156.4 +_ 46.3 * 208.2 _+ 33.9 * 157.5 +_ 47.1 * 158.2 +_ 30.1 * 140.4 _+ 31.2 
trans-2,cis-6-Nonadienal 2.7 + 0.8 3.8 + 1.2 * 9.4 + 3.8 * 4.9 + 0.9 * 3.9 + 1.0 3.2 + 1.1 
trans,trans-2,4-Nonadienal 26.8 ± 1.8 27.9 + 4.3 31.2 + 4.1 * 77.3 + 10.6 25.8 ± 4.2 24.0 4- 6.8 
4-Hydroxy-non-2-enal 86.0 + 14.2 142.7 _+ 38.9 * 189.7 + 72.6 * 135.1 + 53.6 * 86.9 ± 27.6 94.3 + 9.4 
Decanal 165.6 + 59.1 198.3 + 34.2 278.1 + 74.9 * 197.1 ± 89.6 159.9 ± 60.2 162.2 ± 51.3 
trans-4,cis-4-Decenal 56.8 + 9.4 92.9 ± 14.6 * 141.8 _+ 47.4 * 111.1 ± 21.6 * 89.2 _+ 20.9 * 81.5 + 32.7 * 
Dodecanal 163.7 ± 32.0 185.3 ± 77.2 289.4 _+ 38.7 * 250.1 ± 37.8 * 212.4 ± 55.1 * 167.7 ± 37.6 
Malondialdehyde 299.0 ± 53.7 312.6 ± 67.4 452.5 ± 85.8 * 410.5 _+ 86.5 * 363.8 ± 69.6 354.1 ± 50.9 
3-Hydroxyheptan-2-one 105.1 ± 15.9 129.8 ± 15.3 * 75.3 ± 11.8 * 70.9 ± 15.3 * 82.5 ± 14.2 * 108.7 _+ 14.7 
3-Hydroxyoctan-2-one 18.7 ± 2.0 22.7 ± 7.0 18.9 ± 3.4 19.2 ± 1.6 21.1 ± 7.0 19.4 + 2.3 
3-Hydroxynonan-2-one 11.4_+ 1.9 17 .6±5.8  * 8 .9± 1.7 ~ 7 .5±2.1  * 4 .8± 1.6 * 4.1 ±2.7  * 
3-Hydroxydecan-2-one 106.9 ± 18.5 132.1 ± 46.7 100.5 ± 40.6 92.0 ± 13.9 73.3 _+ 6.0 * 61.0 ± 5.0 * 
3-Hydroxydodecan-2-one 89.5 ± 15.4 94.5 ± 32.7 87.6 ± 30.8 67.4 ± 18.8 * 75.7 ± 32.9 45.6 ± 12.2 * 
Data presented as mean _+ SD (nmol / l ) ,  * P < 0.01, * P < 0.05 compared with control. 
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DOX treatment, and then significantly decreased. The 
ratio of aldehydes to acyloins, which reflects the 
proportion of saturated aldehydes detoxified by Pyru- 
vate Dehydrogenase (PDH) to acyloins, increased 
following DOX treatment. The plasma ratio doubled 
at 2 h, then declined towards control values. There 
was a significant, sustained decrease of acyloins in 
heart tissue following DOX treatment. In heart the 
ratio increased more than four-fold by 2 h suggesting 
that the increase in toxic aldehydes was accompanied 
by inhibition of the detoxification mechanisms, possi- 
bly because of decreased PDH activity. 
Tables 1 and 2 showed the individual aldehyde and 
acyloin concentrations in rat plasma and heart tissue 
following DOX treatment. There was a remarkable 
increase in most aldehydes with a peak around 2 h. 
Significant changes of some well-known toxic alde- 
hydes included hexanal, 4-hydroxy-non-2-enal (HNE) 
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Fig. 3. GSH and GSSG levels in rat blood following DOX 
treatment. GSH and GSSG levels in rat blood following DOX 
treatment (A, GSH; B, GSSG). Data presented as mean ± SEM. 
*P <0.01 ,  * P <0.05 .  
increase followed by decreases in some of the acy- 
loins in rat plasma, while most of the acyloins in rat 
heart decreased significantly. 
Table 2 
Aldehydes and acyloins concentration in rat heart following doxorubicin treatment 
Aldehydes and Acyloins Rat-control Rat-l h Rat-2 h Rat 4 h Rat-8 h Rat-24 h 
(n = 12) (n  = 4) (n  = 4) (n  = 4) (n  = 4) (n  = 4) 
Propanal 60.5 ± 8.9 150.6 ± 30.8 * 260.8 ___ 49.2 * 192.0 ± 24.5 * 118.6 ± 29.6 * 74.1 ± 
Butanal 15.1 ± 4.3 42.0 ± 6.8 * 88.9 ___ 24.7 * 55.2 _+ 16.4 * 35.8 ± 3.4 * 22.3 ± 
Pentanal 10.3 ± 4.3 25.3 ± 4.9 * 73.8 ± 21.0 * 61.5 ± 23.6 * 22.6 ± 9.7 * 10.6 +_ 
Furfural 2.8 _+ 0.8 13.0 ± 1.2 * 21.9 ± 1.9 * 14.1 ± 2.9 * 8.2 ± 4.5 * 5.2 ± 
Hexanal 138.0_+ 26.0 277.5_+ 24.6 * 417.4 ± 100.5 * 271.0 ± 41.2 * 187.9 +_ 51.3 * 159.6 ± 
trans-2-Hexenal 13.0 _+ 1.1 35.4 ± 10.8 * 45.1 ± 7.2 * 30.0 ± 5.9 * 15.9 ± 5.2 13.5 ± 
Heptanal 157.6 ± 26.8 251.0 ± 64.6 * 362.8 ± 69.0 * 221.4 ± 16.3 * 175.6 ± 14.4 159.1 ± 
trans-2-Heptenal 99.4 ± 35.8 219.9 ± 81.7 * 324.2 ± 61.3 * 214.1 ± 76.4 * 150.3 ± 42.5 * 112.9 ± 
trans,trans-2,4-Heptadienal 21.4 _+ 4.8 21.5 ± 2.2 28.7 ± 10.6 27.5 _+ 10.8 19.4 ± 4.1 19.5 _+ 
Octanal 191.6 ± 27.9 268.1 ± 19.9 * 348.4 ± 88.9 * 263.3 _+ 26.3 * 213.8 ± 14.4 187.9 ± 
trans-2-Octenal 12.5 ± 3.1 19.9 ± 3.2 * 22.3 ___ 5.4 * 18.4 ± 1.3 * 14.4 ± 3.9 17.1 ± 
Nonanal 241.1 ± 71.6 248.8 ± 38.4 362.7 ± 136.5 * 207.6 ± 46.1 232.7 _+ 107.5 219.7 ± 
trans-2-Nonenal 95.0 ± 20.4 205.8 ± 84.2 * 224.2 ± 60.3 * 182.6 ± 39.0 * 142.8 ± 54.3 * 104.5 ± 
trans-2,cis-6-Nonadienal 2.4 ± 0.7 5.1 ± 2.7 * 9.6 ± 2.2 * 4.5 ± 2.6 * 3.7 _+ 2.4 2.5 ± 
trans,trans-2,4-Nonadienal 14.8 ± 4.8 16.3 ___ 3.2 19.9 ± 5.6 14.4 _+ 4.8 16.5 ± 1.4 13.6 ± 
4-Hydroxy-non-2-enal  61.7 ± 20.6 126.9 ± 13.3 * 194.7 ± 40.8 * 101.5 ± 37.6 * 85.7 ± 28.7 76.2 ± 
Decanal 57.1 ± 15.5 127.9___36.7 * 179 .7±39.2  * 101.1 ±55.3  * 95 .9+41.4  * 85.7_+ 
trans-4,cis-4-Decenal 107.5 ± 16.5 162.4 ± 33.0 * 187.9 ± 23.8 * 139.7 ± 28.3 * 115.2 ± 29.5 93.7 ± 
Dodecanal 100.2 ± 13.4 209.6 _+ 53.5 * 238.2 + 53.8 * 163.9 _+ 47.5 * 112.8 + 40.3 100.4 ± 
Malondialdehyde 245.5 ± 50.0 439.3 ± 94.2 * 872.6 ± 159.9 * 704.8 ± 195.8 * 564.1 _+ 162.3 * 405.4 ± 
3-Hydroxyheptan-2-one 32.2 ± 9.8 20.2 ± 7.3 * 21.0 ± 6.2 24.4 ± 6.9 27.3 _+ 7.3 24.1 ± 
3-Hydroxyoctan-2-one 10.6 ± 1.4 9.0 ± 0.9 7.1 ± 2.5 * 4.4 ± 2.2 * 3.8 ± 1.6 * 4.3 _+ 
3-Hydroxynonan-2-one 12.7 _+ 3.0 8.8 ± 4.6 7.2 ± 5.2 * 4.0 +_ 2.3 * 4.0 ± 2.6 * 5.1 _+ 
3-Hydroxydecan-2-one 35.8 ± 8.9 25.3 ± 5.9 * 20.8 ± 8.6 * 20.1 _+ 6.6 * 13.0 ± 3.6 * 13.5 ± 
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TIME AFTER DOX TREATMENT (h) 
Fig. 4. CK activity in rat plasma following DOX treatment. Data 
presented as mean_SEM.  * P < 0.01, * P < 0.05. 
regression analysis. The equation for this line was 
Y= 2.4788-  0.0404X, and the correlation coeffi- 
cient, r 2 was 0.6480 (P  < 0.01). DOX treatment 
¢¢ 
altered contractility in these rats. The regression line 
for the treated animals (line B) shifted upward, and 
although the relationship was still an inverse linear 
one, the scatter was much greater. The equation for 
the line for the post-DOX animals was Y = 2.2921 - 
0.0183X, and r 2 was 0.3017 (P  > 0.05). After DOX, 
contractility was enhanced in some of animals, while 
in others the shift from normal to abnormal suggested 
a functional impairment, he changes however were 
not consistent. 
Fig. 3 showed the GSH (A) and GSSG (B) levels 
in rat blood following DOX treatment. GSH levels 
decreased early (4 and 8 h), and increased by 24 h, 
while GSSG levels were reduced at 1 h, and signifi- 
cantly elevated 4-24 h after DOX treatment. 
CK activity in rat plasma following DOX treat- 
ment was shown in Fig. 4. CK levels were signifi- 
cantly elevated in all time point following DOX 
treatment. 
Fig. 5 showed the wall stress/Vet. ~ relationship in 
normal and DOX-treated rats. The relationship be- 
tween wall stress and the velocity of circumferential 
fiber shortening is an index of contractility. This was 
determined to be a normal inverse linear one in our 
control rat population. Line A in Fig. 9 is from the 
control rats, and was obtained by least square linear 
' 1 [ • NOR~ 
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Fig. 5. Wall stress/Vcf e relationship in normal and DOX treated 
rats. Linear regression between wall stress and Vcf c for control 
animals is represented by line A (Y= 2.4788-0.040X,  r 2= 
0.6480, P < 0.01). Line B (Y = 2.2921 -0.0183X,  r 2 = 0.3017, 
P > 0.05) is from post-DOX treated animals. 
4. Discussion 
Free radicals are generally short lived and thus 
inflict damage only in the local environment where 
they are produced. Recent findings indicate that lipid 
peroxidation also results in the production of a great 
variety of stable, diffusible saturated and unsaturated 
aldehydes including MDA, 4-hydroxy-alkenals, alka- 
nals, 2-alkenals, and 2,4-alkadienals. The cytotoxic 
aldehydes are extremely active, they can diffuse 
within or even escape from the cell and attack targets 
far from the site of the original free radical initiated 
event, and therefore act as 'second cytotoxic messen- 
gers' [19,22,23]. Among them, HNE is an o~,/3-un- 
saturated aldehyde that can be formed by peroxida- 
tion of 09-6 unsaturated fatty acids such as linoleic 
and arachidonic acids [24]. HNE originates almost 
exclusively from phospholipid-bound arachidonic acid 
and may be a highly reliable index of free-radical 
induced lipid peroxidation. HNE exhibits a variety of 
cytopathological effects such as enzyme inhibition, 
inhibition of DNA and RNA synthesis, inhibition of 
protein synthesis, and induction of heat shock pro- 
teins. It also shows genotoxic and mutagenic effects 
as well as inhibitory effects on cell proliferation 
[22,25,26]. 
Aldehydes are potent cytotoxic agents that react 
with different biomolecules, thus changing the bio- 
chemical status of the cell, resulting finally in cell 
damage [27]. Our data clearly demonstrate hat the 
aldehydes in rat plasma and heart tissue increased 
significantly following in vivo DOX treatment. The 
changes occurred early, peaked around 2 h after DOX 
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administration, and the levels declined or returned to 
normal values within 8-24 h. These changes in- 
cluded some of the well-known toxic aldehydes uch 
as hexanal, HNE and MDA. 
Recently studies have shown that pyruvate dehy- 
drogenase (PDH) catalyzes a little known conjugation 
reaction between pyruvate and saturated aldehydes to 
produce acyloins (3-hydroxyalkan-2-ones), which can 
then be reduced endogenously to the corresponding 
2,3-alkanediols. Since acyloins and 2,3-alkanediols 
are stable and freely diffusible, PDH could catalyze 
an alternative and ubiquitous detoxification mecha- 
nism for saturated aldehydes produced by lipid per- 
oxidation [28,29]. We found that the acyloin levels 
increased and then decreased in plasma, and there 
was a significant decrease of acyloins in heart tissues 
after DOX treatment. Although the metabolic detoxi- 
fication of toxic aldehydes i not well understood, our 
data suggest hat there may be an inhibition by DOX 
of PDH, or of the PDH-Acyloin Synthase (PDH-AS) 
activity. An impairment of PDH and/or PDH-AS 
activity may play a role in DOX-induced cardio- 
toxicity. 
The body has elaborate defenses to prevent injury 
caused by free radical-induced lipid peroxidation. 
The enzyme systems functioning in this capacity 
include catalase, superoxide dismutase (SOD), glu- 
tathione peroxidase (GP), and a number of free radi- 
cal scavengers such as glutathione (GSH), Vitamins 
E and A, etc. [24,27,30-32]. GSH levels decreased 
early, then increased by 24 h, while GSSG levels 
decreased, then increased after DOX treatment, sug- 
gesting a early depletion of GSH and later overcom- 
pensation. GSH, a tripeptide synthesized by glu- 
tathione synthetase, is thought o be one of the most 
effective primary antioxidants against oxidizing 
agents. The electron-rich sulfhydryl group in GSH 
can neutralize free radicals or conjugate with aldehy- 
des and intercept their reactions with cell con- 
stituents. GSH synthetase r quires 1-2 h to return the 
GSH level to its original or even higher concentra- 
tions after detecting a reduction in the cellular GSH 
concentration [27,33]. A bolus injection of a large 
dose of DOX will induce an overwhelming oxidative 
stress and may cause the depletion of some anti- 
oxidants. 
Echocardiography is one of the most important 
techniques for early detection of anthracycline- 
induced cardiomyopathy [8,34]. In our study, we 
were able to evaluate the relationship between the 
wall stress and the velocity of circumferential fiber 
shortening in normal rats. CK levels were elevated 
after DOX administration, indicating myocardial in- 
jury. Our results indicated that in some of the animals 
following treatment there was a shift from normal to 
abnormal (increased or decreased contractility) as a 
consequence of DOX exposure, this however was not 
a consistent finding. Acute, transient effects of DOX 
have been reported to included tachycardia, rrhyth- 
mias, and increased beta adrenergic tone. The in- 
creased contractility in some animals may be a reflec- 
tion of these changes. Since the cardiac functional 
abnormalities following DOX treatment have been 
documented to occur much later than the initial bio- 
chemical changes presented here, a few hours or days 
might be too short a period for the development of an 
overt cardiomyopathic process. 
DOX is eliminated from the body within 2 days 
after administration, and the increase in hydroxyl 
radicals and cytotoxic aldehydes i an early transient 
event. In contrast, in human subjects who have been 
treated with DOX, cardiomyopathy may take months 
or years to develop fully. The development of DOX- 
induced cardiomyopathy must therefore be due to a 
complex sequence of events in which the presence of 
DOX is required only at the beginning to initiate the 
process. Our hypothesis i that the cytotoxic aldehy- 
des produced as a consequence of DOX-induced lipid 
peroxidation are the main culprits of the short-term 
abnormalities, and initiate the signals leading to the 
chronic, long-term injury, particularly with repeated 
exposure as in humans. The reactions initiated by the 
cytotoxic aldehydes result in impaired energy produc- 
tion, membrane damage, protein and DNA damage, 
and the induction of inflammatory reactions leading 
to increased synthesis of adhesion molecules and 
cytokines,  infiltration of neutrophi ls and 
macrophages, and necrotic or apoptotic death of heart 
cells. 
The present study confirms the involvement of free 
radicals, and suggests that cytotoxic aldehydes play a 
key role in initiating the steps that lead to functional 
impairment of the myocardium following DOX ad- 
ministration. Scavengers and the metabolic removal 
of some of these aldehydes also play a role in 
protecting the myocardium against injury. Further 
52 X. Luo et al. / Biochimica et Biophysica Acta 1360 (1997) 45-52 
investigations concerning the cascade of events fol- 
lowing DOX treatment that lead ultimately to car- 
diomyopathy, and a study of the effectiveness of 
specific cardioprotective agents to interfere with the 
initial biochemical changes are underway in our labo- 
ratory. 
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